| Overview |
| bsm-51428M |
| MAGED1 (5C7) Monoclonal Antibody |
| WB |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| This MAGED1 antibody is generated from a mouse immunized with a KLH conjugated synthetic peptide between 20-224 amino acids from the Central region of human MAGED1. |
| Monoclonal |
| #REF! |
| IgG1 |
| 0.5ug/ul |
| Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein G column, followed by dialysis against PBS. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C for 12 months. |
| Target |
| 9500 |
| Q9Y5V3 |
| NRAGE; DLXIN-1; Melanoma-associated antigen D1; MAGE tumor antigen CCF; MAGE-D1 antigen; Neurotrophin receptor-interacting MAGE homolog; MAGED1; PP2250; PRO2292 |
| Involved in the apoptotic response after nerve growth factor (NGF) binding in neuronal cells. Inhibits cell cycle progression, and facilitates NGFR-mediated apoptosis. May act as a regulator of the function of DLX family members. May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. Plays a role in the circadian rythm regulation. May act as RORA co-regulator, modulating the expression of core clock genes such as ARNTL/BMAL1 and NFIL3, induced, or NR1D1, repressed. |
| Application Dilution |
| WB |
1:300-5000 |